Skip to content

Study · Non-randomized trial · n = 71 · 2021

4 results

Recombinant human thymosin beta-4 (rhTβ4) improved scalp condition and microbiome homeostasis in seborrheic dermatitis.

Yu R, Lin Q, Zhai Y, Mao Y, Li K, Gao Y, Liu Y, Fu L, Fang T, Zhao M, Guan L, Hou L, Xu J, Chen W

Microbial biotechnology28 Jul 2021Cited by 7 (Europe PMC)

PMID34318587 (opens in a new tab)PMCIDPMC8449661 (opens in a new tab)DOI10.1111/1751-7915.13897 (opens in a new tab)PepBankPUB-34318587
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with seborrheic dermatitis, rhTβ4 gel gave significantly greater efficacy than ketoconazole lotion.

    In plain wordsIn people with seborrheic dermatitis, the rhTβ4 gel worked better than ketoconazole lotion.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseEfficacy in scalp seborrheic dermatitis versus ketoconazole
    Study

    n = 71

    Comparator
    2% ketoconazole lotion
    Outcome group
    Skin and hair · Skin and wound
    Studied dose
    0.5 mg/ml gel · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    The rhTβ4 treatment provided significantly greater efficacy than ketoconazole
    1 context sentence
    Summary · context
    We investigated the benefit of a 4-week treatment with 0.5 mg ml-1 recombinant human thymosin β4 (rhTβ4) gel or 2% ketoconazole lotion on the scalp condition of 71 patients with SD compared with 21 healthy individuals.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with seborrheic dermatitis, rhTβ4 gel gave a sustained effect in treating scalp disease.

    In plain wordsIn people with seborrheic dermatitis, the rhTβ4 gel had a lasting effect on the scalp.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseSustained effect on scalp seborrheic dermatitis
    Study

    n = 71

    Outcome group
    Skin and hair · Skin and wound
    Studied dose
    0.5 mg/ml gel · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    and a sustained effect in the treatment of scalp SD.
    1 context sentence
    Summary · context
    We investigated the benefit of a 4-week treatment with 0.5 mg ml-1 recombinant human thymosin β4 (rhTβ4) gel or 2% ketoconazole lotion on the scalp condition of 71 patients with SD compared with 21 healthy individuals.
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients with seborrheic dermatitis, rhTβ4 improved microbiome homeostasis and shifted scalp microflora toward a healthy composition.

    In plain wordsIn people with seborrheic dermatitis, the rhTβ4 gel moved scalp microbes toward a healthy mix.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    Direction not reportedScalp microbiome homeostasis
    Study

    n = 71

    Outcome group
    Infection and antimicrobial activity · Skin and wound
    Studied dose
    0.5 mg/ml gel · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    More importantly, rhTβ4 dramatically improved the microbiome homeostasis and prompted a shift of scalp microflora towards healthy composition
    1 context sentence
    Summary · context
    We investigated the benefit of a 4-week treatment with 0.5 mg ml-1 recombinant human thymosin β4 (rhTβ4) gel or 2% ketoconazole lotion on the scalp condition of 71 patients with SD compared with 21 healthy individuals.
  4. 04HumanNon-randomized trialEfficacy outcome

    In patients with seborrheic dermatitis, rhTβ4 helped symptoms and ameliorated physiological conditions more effectively and durably than ketoconazole.

    In plain wordsIn people with seborrheic dermatitis, the rhTβ4 gel improved symptoms and skin measures more and for longer than ketoconazole.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseSymptoms and physiological conditions versus ketoconazole
    Study

    n = 71

    Comparator
    2% ketoconazole lotion
    Outcome group
    Skin and hair · Skin and wound
    Studied dose
    0.5 mg/ml gel · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    helping symptoms and ameliorating physiological conditions more effectively and durably than ketoconazole.
    1 context sentence
    Summary · context
    We investigated the benefit of a 4-week treatment with 0.5 mg ml-1 recombinant human thymosin β4 (rhTβ4) gel or 2% ketoconazole lotion on the scalp condition of 71 patients with SD compared with 21 healthy individuals.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.